Valuation: Simulations Plus, Inc.

Market Cap 371M 326M 303M 278M 522M 35.72B 530M 3.6B 1.41B 17.56B 1.39B 1.36B 60.72B P/E 2026 *
43.7x
P/E 2027 * 40.1x
Enterprise Value 371M 326M 303M 278M 522M 35.72B 530M 3.6B 1.41B 17.56B 1.39B 1.36B 60.72B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.08%
Yield 2026 *
-
Yield 2027 * -
1 day+0.05%
1 week+0.60%
Current month+0.16%
1 month+0.94%
3 months+25.96%
6 months-12.00%
Current year+0.60%
1 week 18.19
Extreme 18.19
18.38
1 month 18.14
Extreme 18.145
18.68
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.87
Extreme 7.87
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Sell

Executive/Senior Manager

-1,000 0.0050%
1/7/26 Sell

Founder

-4,177 0.0207%
16/6/26 Fiscal year

Executive/Senior Manager

22,050 0.1094%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%+0.60%+39.79%-61.89% 371M
+3.71%-4.68%-36.05%-5.45% 30.25B
-1.42%-14.59%-50.04%+138.50% 11.68B
+1.76%-3.42%-27.38%+57.74% 5.28B
-1.99%-3.05% - - 2.08B
+2.86%-10.62%+45.75%-34.09% 1.86B
-3.11%-1.18% - - 1.72B
-3.12%-3.55%-39.08% - 1.03B
-2.01%-3.95%+35.19%+102.78% 865M
-4.53%-4.82%-44.46%-57.70% 723M
Average -0.78%-4.98%-9.54%+19.98% 5.59B
Weighted average by Cap. +1.66%-6.60%-33.83%+33.66%

Financials

2026 *2027 *
Net sales 81.87M 71.91M 66.87M 61.37M 115M 7.88B 117M 794M 310M 3.88B 307M 301M 13.4B 86.26M 75.76M 70.46M 64.65M 121M 8.31B 123M 837M 327M 4.08B 324M 317M 14.12B
Net income 9.53M 8.37M 7.79M 7.15M 13.43M 918M 13.63M 92.47M 36.13M 451M 35.79M 35.02M 1.56B 10.18M 8.94M 8.32M 7.63M 14.34M 980M 14.56M 98.75M 38.58M 482M 38.22M 37.4M 1.67B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
24/07/26 USD 18.34 +0.05% 240,703
23/07/26 USD 18.33 +0.44% 571,006
22/07/26 USD 18.25 +0.11% 1,066,345
21/07/26 USD 18.23 +0.11% 2,071,404
20/07/26 USD 18.21 -0.11% 504,896
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.34USD
Average target price
17.25USD
Spread / Average Target
-5.94%

Quarterly revenue - Rate of surprise